| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 6.40 Billion | USD 26.60 Billion | 19.50% | 2024 |
FrequentlyAsked Questions
Psychiatric digital biomarkers are quantifiable and objective data collected through digital tools, such as wearable devices, applications, and smartphones, that help monitor, detect, and predict mental health conditions. These biomarkers study physiological, behavioral, and cognitive patterns, such as social interaction, movement, speech, and sleep, to support the treatment and diagnosis of various disorders.
The global psychiatric digital biomarkers market is projected to grow due to improvements in digital phenotyping, increased support from pharmaceutical companies, rising awareness, and a decrease in stigma.
According to study, the global psychiatric digital biomarkers market size was worth around USD 6.40 billion in 2024 and is predicted to grow to around USD 26.60 billion by 2034.
The CAGR value of the psychiatric digital biomarkers market is expected to be approximately 19.50% from 2025 to 2034.
North America is expected to lead the global psychiatric digital biomarkers market during the forecast period.
The key players profiled in the global psychiatric digital biomarkers market include Mindstrong Health, Akili Interactive, Pear Therapeutics, Cognoa, Koa Health, Quartet Health, Headspace Health, Spring Health, Ginger, Behavioral Signals, Joon Health, Empatica, Otsuka Digital Health, Neurotrack Technologies, and NeuroFlow.
The report examines key aspects of the psychiatric digital biomarkers market, including a detailed discussion of existing growth factors and restraints, as well as future growth opportunities and challenges that impact the market.
HappyClients